Key Regulatory Approval Details
- The European Commission granted marketing authorization for Pebrilzo®, Biocon's biosimilar pertuzumab, on November 18, 2026
- This is the first biosimilar to receive EC marketing authorization under the European Medicines Agency's new tailored clinical approach
- The approval follows positive CHMP opinion received on September 17, 2026
- This approval comes after recent U.S. FDA approval for the same biosimilar
Product Specifications
- Drug Name: Pebrilzo® (biosimilar pertuzumab)
- Dosage Form: 420 mg concentrate for solution for infusion
- Classification: Biosimilar medicinal product
- Active Substance: Pertuzumab, a monoclonal antibody
- Mechanism: Binds with high affinity and specificity to human epidermal growth factor receptor 2 (HER2), inhibiting proliferation of tumour cells that overexpress HER2
Indications and Usage
Approved for treatment of HER2-positive breast cancer across multiple disease stages:
1. Neoadjuvant treatment: In combination with trastuzumab and chemotherapy for adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence
2. Adjuvant treatment: In combination with trastuzumab and chemotherapy for adult patients with HER2-positive early breast cancer at high risk of recurrence
3. Metastatic treatment: In combination with trastuzumab and docetaxel for adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
Scientific Basis for Approval
Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon's pertuzumab biosimilar is highly similar to the reference product with no clinically meaningful differences in quality, safety, or efficacy.
Strategic Significance
- This marks Biocon's fifth oncology biosimilar approved in both Europe and the United States
- Strengthens Biocon's global oncology portfolio
- Supports company's commitment to expanding access to high-quality, affordable biologic therapies
- Addresses treatment needs for patients with HER2-positive breast cancer
- Supports more sustainable healthcare systems in Europe
Epidemiology Context
According to 2024 estimates from the European Cancer Information System (ECIS):
- Breast cancer remains the most commonly diagnosed cancer among women in Europe
- Leading cancer diagnosis among women across Europe
- Approximately 15–20% of invasive breast cancers are characterized by HER2 overexpression or amplification
Company Background
Biocon Limited is a global biopharmaceutical company headquartered in Bengaluru, India. The company has commercialized 12 biosimilar products and 30+ generic formulations globally, with a robust R&D pipeline of 20+ biosimilar assets, GLP-1 peptides, and other complex generics. The company operates in more than 120 countries with seven manufacturing sites, three R&D sites, 18 offices worldwide, and over 9,500 employees.